Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- New trial
Multiple myeloma
Phase 2 Study of Elranatamab Plus Isatuximab in Relapsed and Refractory Multiple Myeloma
MGH is launching an open-label phase 2 trial evaluating subcutaneous elranatamab in combination with investigational isatuximab for RRMM patients after at least two prior therapies, including IMiDs and proteasome…
NCT06832865 - New trial
Head and neck cancer
Phase I Study: Zanzalintinib with Pembrolizumab and Cetuximab in Recurrent/Metastatic HNSCC
University of Chicago is evaluating the safety, tolerability, and optimal dosing of zanzalintinib—a dual cMet and VEGFR inhibitor—in combination with cetuximab and pembrolizumab in a Phase I dose-escalation/expansion…
NCT06912087 - New trial
Head and neck cancer
Window Trial of Fluorescently Labeled Panitumumab in Head and Neck Cancer
This trial at Vanderbilt is evaluating Panitumumab-IRDye800 in resectable HNSCC to optimize dosing and enhance tumor visualization during surgery. The study aims to refine the balance between effective cancer imaging…
NCT06819228 - New trial
Colorectal cancer
A Phase II Trial of Tiragolumab in Combination With Atezolizumab and Bevacizumab in Patients With Previously Treated, Microsatellite Stable, Metastatic Colorectal Adenocarcinoma
This trial is evaluating whether combining tiragolumab, atezolizumab, and bevacizumab can safely and effectively treat advanced MSI-stable colorectal cancer, with assessments including imaging, labs, and optional…
NCT06784947 - New trial
Liver and bile duct cancer
Phase II Study of Atezolizumab, Bevacizumab and Memantine in Hepatocellular Carcinoma
Inova is evaluating a triplet regimen—adding memantine to the standard atezolizumab and bevacizumab therapy—in locally advanced/unresectable hepatocellular carcinoma patients over 21-day cycles for six months.
NCT06789757 - New trial
Liver and bile duct cancer
A Pilot Study of 68Ga-PSMA-11 PET-directed Radioligand Therapy in Patients with Metastatic Hepatocellular Carcinoma (HCC)
This pilot study is evaluating the safety and efficacy of 177Lu-PSMA-617 radioligand therapy in PSMA-positive metastatic or unresectable HCC patients who have progressed on second-line treatments, including prior…
NCT06852820 - New trial
Liver and bile duct cancer
Regorafenib and Yttrium-90 Radioembolization for Unresectable HCC
A trial is underway at Miami to assess the impact of combining Regorafenib with Y-90 trans-arterial radioembolization in patients with unresectable hepatocellular carcinoma over an estimated 37-month period.
NCT06902246 - New trial
Sarcoma and GIST
Phase 1b/2 Study of ERAS-601 SHP2 Inhibitor as Monotherapy in Advanced Chordoma
Memorial Sloan Kettering is investigating whether ERAS-601, a SHP2 inhibitor, can safely and effectively treat advanced, progressing chordoma. The single-arm trial administers ERAS-601 at 40mg BID on a 3-weeks-on,…
NCT06957327 - New trial
Myeloproliferative neoplasms
Phase III Trial of Benralizumab in Hypereosinophilic Syndrome
A multicentre, randomised, double-blind, placebo-controlled study will evaluate benralizumab versus placebo over a 24-week period, with an open-label extension for eligible HES patients. AstraZeneca is assessing…
NCT04191304 - New trial
Neuroendocrine and adrenal tumors
18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma
This pilot study at St. Jude is evaluating the safety and biodistribution of 18F-DA in pediatric patients with neuroblastoma or pheochromocytoma, while comparing its imaging clarity with the current standard,…
NCT03541720 - New trial
Kidney cancer
Phase II Study of Total MPDT in Metastatic Clear Cell RCC
This open-label phase II trial evaluates total consolidative metastasis-and-primary directed therapy (MPDT) in metastatic clear cell RCC patients with partial response or stable disease after at least 6 months of…
NCT06770855 - New trial
Sarcoma and GIST
An Open-Label, Multicenter, Phase 2 Study with Safety Lead-In of Intratumoral VO Plus Pembrolizumab in Angiosarcoma
This phase 2 trial is evaluating the safety of intratumoral VO combined with pembrolizumab in patients with locally advanced or metastatic angiosarcoma who have progressed following prior immunotherapy, with an…
NCT06898970 - New trial
Multiple solid tumors
Phase 1a/1b Trial of LY3962673 in KRAS G12D-Mutant Solid Tumors
Eli Lilly and Company is evaluating LY3962673—an oral KRAS (G12D) inhibitor—as a monotherapy and in combination with various chemotherapy agents in patients with advanced, unresectable solid tumors. The study…
NCT06586515 - New trial
Multiple solid tumors
Phase I/II Trial: GDC-7035 in KRAS G12D-Mutant Advanced Solid Tumors
Genentech, Inc. is conducting a first-in-human, open-label study to assess the safety, pharmacokinetics, and preliminary efficacy of GDC-7035—a KRAS (G12D) inhibitor—administered both as a single agent and in…
NCT06619587 - New trial
Multiple solid tumors
Phase I Study: MTI-301 in Advanced/Metastatic/Refractory Solid Tumors
Mayo Clinic is assessing MTI-301—a first-in-human SCD1 inhibitor—as monotherapy in patients with unresectable or metastatic solid tumors with no standard care options. Participants receive MTI-301 orally once daily…
NCT06911008 - New trial
Multiple solid tumors
Phase 1 Study of TGW101 in Advanced Solid Tumors
Tagworks Pharmaceuticals BV is evaluating TGW101—a TAG72-directed antibody-drug conjugate administered via IV infusion followed by TRG001—in a first-in-human study in patients with various advanced solid tumors,…
NCT06959706 - New trial
Multiple solid tumors
Phase I Study: BNT317 in Advanced Solid Tumors
BioNTech SE is conducting a first-in-human, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of BNT317—a CD39-directed monoclonal antibody—as monotherapy in…
NCT06750185 - New trial
Multiple solid tumors
Phase I/II Study of IPN01195 in Advanced Solid Tumours with MAPK Alterations
Ipsen is evaluating IPN01195—a MAPK1 inhibitor—as monotherapy in adults with advanced solid tumours (with MAPK alterations) who have no standard care options. The study includes a dose-escalation phase to determine…
NCT06833008 - New trial
Multiple solid tumors
Phase 1 Study of IBI3020 in Advanced Solid Tumors
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. is evaluating IBI3020—a CEACAM5-directed monoclonal antibody—in a multicenter, open-label Phase 1 trial for patients with unresectable, locally advanced or…
NCT06963281 - New trial
Multiple solid tumors
Phase I/1b Study: ODC-IL2 in Advanced Solid Tumors
Trutino Biosciences Inc. is conducting a first-in-human, multicenter, open-label trial to evaluate the safety, pharmacodynamics, pharmacokinetics, and antitumor activity of ODC-IL2—a conditionally activated IL-2…
NCT06770764 - New trial
Multiple solid tumors
Multicenter Phase 2/3 Study of Ficerafusp Alfa With Pembrolizumab in First-Line PD-L1+ HNSCC
Bicara Therapeutics is evaluating the safety and efficacy of ficerafusp alfa—a dual EGFR/TGFβ inhibitor—combined with pembrolizumab versus placebo plus pembrolizumab in first-line treatment of PD-L1-positive…
NCT06788990 - New trial
Multiple solid tumors
Non-Randomized Phase 2 Trial of Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal SCC
This phase 2 trial is evaluating the safety and tolerability of three CUE-101 dosing schedules as neoadjuvant therapy in HLA-A*0201 positive, HPV16+ oropharyngeal SCC patients before they receive standard definitive…
NCT04852328 - New trial
Multiple solid tumors
Phase I Multicenter Study of Ruxolitinib and Duvelisib in Relapsed or Refractory T- or NK-Cell Lymphomas
MSK is running a phase I trial combining fixed-dose ruxolitinib with dose-escalated duvelisib to assess safety and early signals of efficacy in relapsed/refractory NK/T-cell lymphomas, including ALCL and CTCL. The…
NCT05010005 - New trial
Multiple solid tumors
A Phase I Trial of Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma
Washington University is evaluating whether adding zanzalintinib to eribulin can improve progression-free survival in patients with advanced liposarcoma and leiomyosarcoma resistant to standard therapies by exploring…
NCT06957431 - New trial
Multiple solid tumors
Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment with HER2-targeted Therapy
This pilot study is assessing whether the PET tracer [68Ga]Ga-ABY-025 can enhance detection and visualization of lesions in HER2+ solid tumors during standard HER2-targeted treatment. Vanderbilt is leading the trial…
NCT06828588 - New trial
Multiple solid tumors
Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Previously Treated Metastatic Colorectal Cancer
MD Anderson is sponsoring a Phase II trial to evaluate ivonescimab—a bispecific antibody targeting PD-1 and VEGF—in advanced metastatic colorectal cancer patients with distinct mismatch repair statuses, using a…
NCT06959550 - New trial
Multiple solid tumors
Phase 2 Basket Study Evaluating BAY2927088 in HER2-Activated Solid Tumors
Bayer is assessing BAY2927088—an oral EGFR and HER2 inhibitor—in adults with metastatic or unresectable solid tumors harboring HER2-activating mutations, including colorectal, biliary, bladder, cervical, and…
NCT06760819 - New trial
Multiple solid tumors
Assessment of Radiation-Induced Vascular Complications in H&N Cancers with PET/CT Imaging
Emory is investigating whether F-18 NaF PET/CT can more effectively assess radiation-induced vascular effects in head and neck cancer patients compared to the standard F-18 FDG PET/CT. The trial targets patients with…
NCT06914999 - New trial
Multiple solid tumors
A Randomized, Phase III Study of Rilvegostomig in Combination With Fluoropyrimidine and T-DXd Versus Trastuzumab, Chemotherapy, and Pembrolizumab for HER2+ Gastric Cancer (ARTEMIDE-Gastric01)
This global Phase III trial is evaluating rilvegostomig combined with T‑DxD and fluoropyrimidine against standard regimens, including trastuzumab and pembrolizumab, as first-line therapy for HER2-positive advanced…
NCT06764875 - New trial
Multiple solid tumors
Phase 1/2 Trial of ENV-501 in Advanced HER3-Expressing Solid Tumors
Endeavor is conducting a first‐in‐human, open‐label study assessing ENV-501’s safety, tolerability, pharmacokinetics, and preliminary efficacy in advanced relapsed/refractory HER3-positive breast, NSCLC, and…
NCT06956690
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.